Lexaria Bioscience Announces New Research Including Cannabinoid Topical Creams and Nicotine Edibles Kelowna, British Columbia

Lexaria Bioscience Announces New Research Including

Cannabinoid Topical Creams and Nicotine Edibles

Kelowna, British Columbia December 15, 2017 Lexaria

Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug

delivery platform innovator, announces a new topical skin cream research and

development ( R&D ) program; R&D into nicotine edibles; and updates

existing R&D programs.

Topical Skin Formulations for Cannabinoids.

has formulated topical cream products as an extension of its DehydraTECH

technology, for the delivery of cannabinoids into and through the skin which may

prove to have emollient benefits desired by the topical products sector.

Lexaria s president, John Docherty M.Sc., has extensive experience as a biotech

company executive and researcher for skin-based delivery of therapeutics.

Multiple Lexaria formulations are scheduled to be laboratory

tested for human skin absorption and penetration characteristics during January

through March 2018. Testing will be completed at a third-party lab utilizing

human skin tissue and the latest in vitro evaluative techniques to

measure cannabidiol penetration in the skin. Lexaria expects to optimize

formulation and manufacturing processes to develop superior-performing product

designs that will potentially be available to licensees during 2018.

Nicotine in Edible Formats.

Lexaria has accelerated

its research focus on nicotine following its recently announced nicotine patent

grant and has been researching edible forms of nicotine which could use the

Company s DehydraTECHTM technology. Formulations have been prepared

and are currently completing quality control testing, prior to in vivo

absorption and tolerability testing in animals.

A third-party Philadelphia based lab has been contracted to

perform the first nicotine edible tests expected in February. In vivo

testing with rats will examine two main outcomes:

distress. Without an enabling technology, untreated nicotine causes

gastrointestinal upset and distress making nicotine edibles impractical. The

DehydraTECHTM process will be evaluated for its ability to lessen

gastrointestinal distress thus potentially opening the door to the creation of a

new line of consumer products.

2) Absorption time and efficiency in crossing

the intestinal wall and reaching the bloodstream. Earlier testing of the

DehyrdaTECHTM process using cannabidiol as an active ingredient, proved reduced absorption times and enhanced

intestinal permeability. It is expected that similar outcomes using nicotine may

University of British Columbia (UBC) TurboCBD Study.

As previously announced, the UBC study was initiated with UBC board

evaluation and approvals. However, a recent change in UBC policy has resulted in

all MITACS/UBC studies of this class to be temporarily halted. This change in

policy affects numerous studies at UBC. Lexaria is currently reviewing methods

of modifying the contemplated UBC study and/or alternatives to complete the

planned study objectives at UBC or elsewhere if necessary and will report on

next steps when they are known.

National Research Council.

The National Research

Council and Lexaria have successfully developed model formulations using the

DehydraTECH process and methodology. Following this completed first phase, the

parties now plan to formulate and test DehydraTECH based cannabinoid

formulations in early 2018 to determine the inherent processes that enable the

palatability and absorption benefits DehydraTECH formulations have

demonstrated. This second phase is expected to be performed with cannabinoids

for the first time to provide additional guidance for further study.

Formulation Experimentation.

Lexaria has conducted

various cannabinoid formulation experiments, together with potential

DehydraTECH licensee partners, on chocolates, candies, gummies, mouth-melts,

chocolate bars, protein bars, beverages such as beer, spices, tea, coffee,

supplements and more.

Beverage formulations have produced cannabinoid water-based

products including de-alcoholized beer that mask unwanted cannabis flavor and

are fast acting. Chocolate formulations were reported as being the fastest

acting, most consistent, and best-tasting products in approximately 70% of cases

in a recent consumer study. As the recreational markets for cannabis become

legal in California and Canada, Lexaria expects increased demand for its

superior-performing edible products. Its formulations further allow clients to

retain organic food claims as the DehydraTECHTM process does not use

Lexaria will work with new and improved formulations for a

variety of food products on a continuous basis throughout 2018 as it broadens

its ever growing universe of products under development for potential licensees.

This should shorten the technology licensing sales cycle and also assist

companies as they collaborate with Lexaria to develop and sell the

highest-performing products in their respective sales categories.

Lexaria Bioscience Corp. has developed

and out-licenses its disruptive delivery technology that promotes healthier

ingestion methods, lower overall dosing and higher effectiveness of lipophilic

active molecules. Lexaria has multiple patents pending in over 40 countries

around the world and has patents granted in the USA and in Australia for

utilization of its DehydraTECHTM delivery technology. Lexaria s

technology provides increases in intestinal absorption rates; more rapid

delivery to the bloodstream; and important taste-masking benefits, for orally

administered bioactive molecules including cannabinoids, vitamins, non-steroidal

anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

For regular updates,

connect with Lexaria:

FOR FURTHER INFORMATION PLEASE CONTACT:

Alex Blanchard, Communications Manager

NetworkNewsWire (NNW)

FORWARD-LOOKING STATEMENTS

This release includes

forward-looking statements. Statements which are not historical facts are

forward-looking statements. The Company makes forward-looking public statements

concerning its expected future financial position, results of operations, cash

flows, financing plans, business strategy, products and services, competitive

positions, growth opportunities, plans and objectives of management for future